pseudoephedrine hydrochloride


Also found in: Dictionary, Thesaurus.
Related to pseudoephedrine hydrochloride: Pseudoephedrine hcl

pseu·do·e·phed·rine hy·dro·chlor·ide

(sū'dō-e-fed'rin hī'drō-klōr'īd),
The naturally occurring isomer of ephedrine; a sympathomimetic amine with actions and uses similar to those of ephedrine.

pseudoephedrine hydrochloride

[-ef′ədrēn]
an adrenergic agonist that acts as a vasoconstrictor and decongestant. Also called pseudoephedrine sulfate.
indication It is prescribed for the relief of nasal congestion.
contraindications Known hypersensitivity to sympathomimetic drugs prohibits its use. Interaction with monoamine oxidase inhibitors may cause hypertensive crisis. It is prescribed with caution in patients who have hypertension, glaucoma, heart disease, diabetes, or urinary retention.
adverse effects Among the more serious adverse effects are central nervous system stimulation, headache, tachycardia, and increased blood pressure.

pseudoephedrine hydrochloride

(soo″dō-ĕ-fĕd′rĭn)
A sympathomimetic drug, an isomer of ephedrine, that has actions similar to those of ephedrine. Trade names is Sudafed.
References in periodicals archive ?
to settle the outstanding patent litigation involving Barr's generic version of Aventis Pharmaceuticals' Allegra(R) D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets.
Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 120 mg, temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies, and nasal congestion associated with sinusitis and temporarily relieves sinus congestion and pressure.
IMPAX Laboratories previously announced FDA acceptance of the Company's ANDA filing for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride 60mg/120mg Extended Release Tablets in February 2002 and commented on the filing of a lawsuit by Aventis alleging patent infringement relating to the ANDA in April 2002.
pseudoephedrine hydrochloride (a decongestant) in each 1 ml of product.
Barr filed an Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets in September 2001, and received notification of the application's acceptance for filing in November 2001.
Barr filed an Abbreviated New Drug Application (ANDA) for Fexofenadine HCI 60 mg capsules in May 2001, an ANDA for Fexofenadine HCI 30 mg, 60 mg, and 180 mg tablets in June 2001, and an ANDA for Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets (marketed by Aventis as Allegra-D) in September 2001.
Pseudoephedrine hydrochloride may produce arrhythmias and cardiovascular collapse with accompanying hypotension or central nervous system stimulation with convulsions.
Barr filed an Abbreviated New Drug Application (ANDA) for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Tablets in September 2001.
s Abbreviated New Drug Application for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets, 60mg/120mg.